Patomekanisme stroke pada infeksi human immunodeficiency virus
Nur Cahyani Setiawati(1*), Paryono Paryono(2), Sekar Satiti(3)
(1) KSM Saraf, RSUD Sragen, Jawa Tengah
(2) Departemen Neurologi, Fakultas Kedokteran-Kesehatan Masyarakat dan Keperawatan Universitas Gadjah Mada, Yogyakarta
(3) Departemen Neurologi, Fakultas Kedokteran-Kesehatan Masyarakat dan Keperawatan Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author
Abstract
Stroke is one of cerebrovascular disease that may occur with or as a result of infection by human immunodeficiency virus (HIV). Direct mechanisms of HIV-related stroke include chronic inflammation associated with atherosclerosis, hypercoagulable state and vasculopathy, while the indirect mechanisms are HIV-related opportunistic infections, the effect of using highly active antiretroviral therapy (HAART), and cardioembolism.
Stimulation of the inflammatory response is estimated to be the predominant mechanism in the relationship between stroke and infections. Inflammatory cascade causing arteriosclerosis, plaque rupture, and thrombosis could result in ischemic stroke while the injury to vascular endothelial cells predisposes hemorrhagic stroke.
The characteristics of HIV infection such as viral load, duration of the disease, therapy with protease inhibitor (PI) and metabolic syndrome parameters (blood sugar, cholesterol and triglycerides, as well as blood pressure measurements) seem to influence the pathogenesis of vascular changes. Combination therapy of antiretrovirals can directly cause arterial tissue injury in which the metabolic complications such as dyslipidemia and insulin resistance may indirectly cause endothelial dysfunction, thus accelerating the occurrence of arteriosclerosis. Provision of HAART also resulted in increased levels of cytokines such as tumour necrosis factor-a (TNF-a), interleukin-1 (IL-1), interleukin-6 (IL-6), and interferon-a that induce apoptosis of subcutaneous adipose tissue in lipodystrophy in HIV patients.
Abstrak
Stroke adalah salah satu penyakit serebrovaskular yang mungkin terjadi bersamaan atau sebagai akibat dari infeksi human immunodeficiency virus (HIV). Mekanisme langsung stroke terkait HIV antara lain peradangan kronis yang berhubungan dengan aterosklerosis, hiperkoagulasi dan vaskulopati, sementara mekanisme tidak langsung adalah infeksi oportunistik terkait HIV, efek penggunaan highly active antiretroviral therapy (HAART) dan kardioemboli.
Stimulasi respons inflamasi diperkirakan menjadi mekanisme predominan hubungan antara stroke dan infeksi. Kaskade inflamasi menyebabkan aterosklerosis, ruptur plak, dan trombosis yang mengakibatkan stroke iskemia, sedangkan perlukaan pada sel endotel vaskular menjadi predisposisi stroke perdarahan.
Karakteristik infeksi HIV sendiri seperti viral load, durasi penyakit, pemberian terapi dengan protease inhibitor (PI) maupun parameter sindrom metabolik (gula darah, kolesterol dan trigliserida, serta pengukuran tekanan darah) nampaknya mempengaruhi patogenesis dari perubahan vaskular yang terjadi. Kombinasi terapi antriretroviral dapat secara langsung menyebabkan perlukaan jaringan arteri di mana komplikasi metabolik seperti dislipidemia dan resistensi insulin secara tidak langsung menyebabkan disfungsi endotel sehingga mempercepat terjadinya aterosklerosis. Pemberian HAART juga mengakibatkan peningkatan level sitokin seperti tumour necrosis factor-a (TNF-a), interleukin-1 (IL-1), interleukin-6 (IL-6), dan interferon-a yang menginduksi apoptosis jaringan adiposa subkutaneus pada lipodistrofi pada pasien HIV.
Keywords
Full Text:
PDFReferences
Benjamin L, Khoo S. HIV infection and stroke. Handbook of Clinical Neurology. 2018;152(3):187–200.
Arvind G, Evangelyne S, Limanukshi A, Bhagyabati Devi S, Jatishwor Singh W. Human immunodeficiency virus - Associated stroke: An aetiopathogenesis study. Journal of Association of Physicians of India. 2013;61:793–797.
Singer EJ, Valdes Sueiras M, Commins DL, Yong W, Carlson M. HIV stroke risk: Evidence and implications. Therapeutic Advances in Chronic Disease. 2013;4(2):61–70.
Nogueira Pinto A. AIDS/HIV infection and cerebrovascular disease. Seminars in Cerebrovascular Diseases and Stroke. 2005;5(1):40–46.
Connor M. Stroke in patients with human immunodeficiency virus infection. Journal of Neurology, Neurosurgery and Psychiatry. 2007;78(12):1291.
Benjamin LA, Bryer A, Emsley HCA, Khoo S, Solomon T, Connor MD. HIV infection and stroke: Current perspectives and future directions. The Lancet Neurology. 2012;11(10):878–890.
Donati KDG, Rabagliati R, Iacoviello L, Cauda R. Review HIV infection, HAART, and endothelial adhesion molecules : current perspectives. The Lancet Infectious Diseases. 2004;4(4):213–222.
Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology. 2011;76(5):444–450.
Vigorito M, Connaghan KP, Chang SL. The HIV-1 transgenic rat model of neuroHIV. Brain, Behavior, and Immunity. 2015;48:336–349.
Fauci AS. HIV and AIDS: 20 Years of science. Nature Medicine. 2003;9(7):839–843.
Gupta S. Antiviral Therapy. Dalam: Paul RH, Sacktor NC, Valcour V, Tashima KT, penyunting. HIV and the Brain: new challenges in the modern era. Vol. 15. New York: Humana Press; 2010.
Calza L, Manfredi R, Pocaterra D, Chiodo F. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. Journal of Infection. 2008;57(1):16–32.
Amado Costa L, Almeida AG. Cardiovascular disease associated with human immunodeficiency virus: A review. Revista Portuguesa de Cardiologia (English Edition). 2015;34(7–8):479–491.
Menteri Kesehatan Republik Indonesia. Peraturan menteri mesehatan Republik Indonesia momor 87 tahun 2014 tentang pedoman pengobatan antiretroviral. Kementerian Kesehatan RI; 2014.
World Healh Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. World Health Organization; 2016.
Maartens G, Celum C, Lewin SR. HIV infection: Epidemiology, pathogenesis, treatment, and prevention. The Lancet. 2014;384(9939):258–271.
Lin HL, Muo CH, Lin CY, Chen HJ, Chen PC. Incidence of stroke in patients with HIV infection: A population-based study in Taiwan. PloS one. 2019;14(5):e0217147.
Alomari AI, Jiarakongmun P, Dejthevaporn C, Pongpech S. Multiple symptomatic cerebral arteriovenous malformations in a patient with HIV. American Journal of Neuroradiology. 2009;30(6):1273–1274.
Venkat A, Piontkowsky DM, Cooney RR, Srivastava AK, Suares GA, Heidelberger CP. Care of the HIV-Positive Patient in the Emergency Department in the Era of Highly Active Antiretroviral Therapy. Annals of Emergency Medicine. 2008;52(3):274–285.
D’Ascenzo F, Quadri G, Cerrato E, Calcagno A, Omedè P, Marra WG, et al. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. Journal of Cardiovascular Medicine. 2015;16(12):839-843.
Palios J, Kadoglou NPE, Lampropoulos S. The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: The emerging role of adipokines. Experimental Diabetes Research. 2011;2012.
Hegde SS, Ismail M, KulamarvaRama S, Abhishek H. Recurrent stroke as the first manifestation in a patient infected with HIVA case report. Journal of AIDS and Clinical Research. 2012;4(4):4–6.
Monsuez JJ, Charniot JC, Escaut L, Teicher E, Wyplosz B, Couzigou C, et al. HIV-associated vascular diseases: Structural and functional changes, clinical implications. International Journal of Cardiology. 2009;133(3):293–306.
Fugate JE, Lyons JL, Thakur KT, Smith BR, Hedley-Whyte ET, Mateen FJ. Infectious causes of stroke. The Lancet Infectious Diseases. 2014;14(9):869–880.
Mavroudis CA, Majumder B, Loizides S, Christophides T, Johnson M, Rakhit RD. Coronary artery disease and HIV; getting to the HAART of the matter. International Journal of Cardiology. 2013;167(4):1147–1153.
Piantino JA, Goldenberg FD, Pytel P, Wagner-weiner L, Ansari SA. Pediatric Neurology Progressive Intracranial Fusiform Aneurysms and T-Cell Immunode fi ciency. Pediatric Neurology. 2013;48(2):130–134.
Khorvash F, Naeini AE, Behjati M, Jalali M. HIV associated thrombocytopenia, misdiagnosed as thrombotic thrombocytopenic purpura: A case report. Cases Journal. 2009;2(10):1–3.
Babina S, Kumar TJ, Roy M, Konjenbam R. Thrombocytopenia in HIV/AIDS. IOSR Journal of Dental and Medical Sciences. 2015;14(11):9–11.
Domingo P, Vidal F, Domingo JC, Veloso S, Sambeat MA, Torres F, et al. Tumour necrosis alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneus adipocyte apoptosis. European Journal of Clinical Investigation. 2005;35(12):771-780.
Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antiviral Therapy. 2007;12(2):149–162.
Ballocca F, Gili S, Ascenzo FD, Grosso W, Cannillo M, Calcagno A, et al. HIV infection and primary prevention of cardiovascular disease: Lights and shadows in the HAART era. Progress in Cardiovascular Diseases. 2016;58(5):565-576.
Antonello VS, Carlos Ferreira Antonello I, Grossmann TK, Tovo CV, Brasil Dal Pupo B, De Quadros Winckler L. Hypertension - An emerging cardiovascular risk factor in HIV infection. Journal of the American Society of Hypertension. 2015;9(5):403–407.
Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A, Monekosso GL. Prevalence of hypertension in HIV/AIDS patients on highly active antiretroviral therapy (HAART) compared with HAART-naïve patients at the Limbe Regional Hospital, Cameroon. PLoS ONE. 2016;11(2):1–11.
Hejazi N, Huang MS, Lin KG, Choong LCK. Hypertension among HIV-infected adults receiving highly active antiretroviral therapy (HAART) in Malaysia. Global Journal of Health Science. 2014;6(2):58–71.
Lima EMO, Gualandro DM, Yu PC, Giuliano I de CB, Marques AC, Calderaro D, et al. Cardiovascular prevention in HIV patients: Results from a successful intervention program. Atherosclerosis. 2009;204(1):229–232.
DOI: https://doi.org/10.22146/bns.v19i1.61893
Article Metrics
Abstract views : 796 | views : 2221Refbacks
- There are currently no refbacks.
Copyright (c) 2020 Berkala NeuroSains
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.